EN DE
STOCK COMPARISON

Quest Diagnostics vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how Quest Diagnostics (DGX) and Thermo Fisher Scientific (TMO) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Quest Diagnostics as the less overvalued of the two: Quest Diagnostics trades at $239 versus a fair value of $164 (-31%), while Thermo Fisher Scientific trades at $580 versus $308 (-47%).
Quest Diagnostics
DGX · USD · Health Care
-31%
upside to fair value
overvalued
Price$239
Fair Value$164
Quality71/100
Thermo Fisher Scientific
TMO · USD · Health Care
-47%
upside to fair value
overvalued
Price$580
Fair Value$308
Quality64/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Quest DiagnosticsThermo Fisher Scientific
Valuation
23.3×P/E (TTM)29.5×
2.07×P/S (TTM)4.41×
3.25×P/B3.74×
12.6×EV/EBITDA20.0×
1.62×PEG1.74×
1.6%Dividend yield0.3%
$3.26Dividend per share$1.76
Profitability
9%Net margin15%
14%Operating margin18%
15%Return on equity14%
6%Return on assets5%
Growth
9%Revenue growth (YoY)6%
3.7%Avg. growth/yr (3Y)-0.3%
3.2%Avg. growth/yr (5Y)6.7%
Balance & size
0.72×Debt / equity0.67×
$23BMarket cap$199B
healthyGrowth qualityhealthy

Quest Diagnostics leads: 10 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Quest Diagnosticsof which business quality 63 · market factors 82 Thermo Fisher Scientificof which business quality 60 · market factors 63
ProfitabilityMargins and returns on capital today
46
43
Quality GrowthAre margins and returns improving?
59
31
CashflowEarnings quality: real cash, not paper profit
69
62
Fin. StrengthBalance sheet, leverage, solvency risk
55
60
InvestmentDisciplined investing over empire-building
70
79
Low VolatilityCalm price path (market factor)
87
68
MomentumPrice trend over the last 3–12 months (market factor)
74
56
52W MomentumDistance to the 52-week high (market factor)
90
68
Net IssuanceBuybacks instead of dilution
89
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Quest Diagnostics

DCF Models$145
Earnings-Based$86.50
Dividend Discount$47.53
Multiples$166
Asset-Based$43.40
Growth DCF$149
Economic Profit$86.32
Growth Earnings$147

25 of 25 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$331
Earnings-Based$203
Multiples$310
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$324

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Quest Diagnostics
Bear $94.57Fair Value $164Bull $242
$239 = current price (white tick)
Thermo Fisher Scientific
Bear $175Fair Value $308Bull $385
$580 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Quest Diagnostics · Health Care

Quality score71 · Top 25%
Fair value upside-31% · below median

Thermo Fisher Scientific · Health Care

Quality score64 · Top 25%
Fair value upside-47% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Quest Diagnostics as the less overvalued of the two: Quest Diagnostics trades at $239 versus a fair value of $164 (-31%), while Thermo Fisher Scientific trades at $580 versus $308 (-47%).

Quest Diagnostics has the higher quality score (71/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.